Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

As more companies are investigating radiopharmaceuticals, the complexities and red tape faced by sponsors are becoming more ...

As the first cohort of patients are dosed in the Phase II trial, multiple new trial sites are added for the glioblastoma ...

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as ...

Real-world evidence (RWE) trials mainly involve observational data outside the traditional involvement of randomised ...

Anocca has submitted its first clinical trial application (CTA) for conducting the Phase I/II VIDAR-1 trial to the EMA.

Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre Phase IIb PROGRESS trial of LX9211 to ...

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...